{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-015144","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.146527+00:00","generated_at":"2026-06-28T10:55:15.686295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immuneering Q3 net loss $8.5M ($0.47/sh); cash $159.6M; IND for IMM-1-104 in Q1 2022","bullets":["Net loss attributable to common stockholders $8.5M vs $4.4M in Q3 2020; diluted EPS $(0.47).","Cash and marketable securities $159.6M as of Sep 30, 2021, up from $37.1M at Dec 31, 2020.","Completed upsized IPO of 8.625M shares at $15.00 each, gross proceeds $129.4M.","IND filing for dual-MEK inhibitor IMM-1-104 expected Q1 2022; Phase 1 trial in 1H 2022.","R&D expenses $6.2M (up from $4.1M); G&A $2.6M (up from $0.7M) due to IPO prep and headcount."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-015144","json":"https://secwatch.observer/filing/0001558370-21-015144.json","markdown":"https://secwatch.observer/filing/0001558370-21-015144.md","text":"https://secwatch.observer/filing/0001558370-21-015144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000155837021015144/0001558370-21-015144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000155837021015144/imrx-20211109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:55:15.686295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}